

ATHENS
GREECE
JANUARY 12



An Initiative of
Encore
Medical
Education

08:10 Welcome addresses

08:15 – 09:15 Session 1: Surgery

08:15-08:30

- POSNOC - Positive sentinel node: Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy.
- Conversion rates from positive to negative axillary involvement in breast cancer patients presenting with biopsy-proven axillary metastases prior to primary systemic therapy (PST) - A transSENTINA subproject.
- **PD8-2.** Residual axillary involvement in early breast cancer in patients with positive sentinel nodes after neoadjuvant chemotherapy (NACT).

08:30-08:45

- **GS6-01.** Surgical treatment after neoadjuvant systemic therapy in young women with breast cancer: Results from a prospective cohort study.
- **GS4-01.** Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: 10 year follow up results of the EORTC AMAROS trial (EORTC 10981/22023).

08:45-09:00

- **GS6-05.** The impact of breast cancer surgery on quality of life: Long term results from E5103.
- **GS6-06.** Local therapy and quality of life outcomes in young women with breast cancer.
- **PD6-09.** Cost effectiveness of bilateral prophylactic mastectomy with and without different breast reconstruction techniques versus screening in women with high risk of breast cancer in the Canadian Province of Ontario.

09:00-09:15 Discussion

ATHENS
GREECE
JANUARY 12



An Initiative of
Encore
Medical
Education

09:15 – 10:15. Session 2: Radiation therapy

09:15 - 09:30

- **GS4-03.** RAPID: A randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT).
- **GS4-04.** Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer.

09:30-09:45

- **GS4-05.** Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003)
- **GS4-02.** Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials

09:45-10:00 Discussant: V. Kouloulis

10:00-10:15 Discussion – local therapy

10:15-10:30 Coffee Break

10:30 – 11:20 Session 3: Breast cancer risk and basic science.

10:30-10:40

- **GS2-01.** Age-related breast cancer risk estimates for the general population based on sequencing of cancer predisposition genes in 19,228 breast cancer patients and 20,211 matched unaffected controls from US based cohorts in the CARRIERS study.



10:40-10:55

- **GS1-03.** Crosstalk between osteoblasts and breast cancer cells alters breast cancer proliferation through multiple mechanisms.
- Clinical utility of circulating tumor cell count as a tool to choose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial.
- **GS5-07.** International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study.

10:55-11:10

- **GS1-07.** The genomic landscape of 501 metastatic breast cancer patients.
- **GS1-06.** Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples.

11:10-11:20. Discussion

11:20 – 12:30 Session 4: Neo-adjuvant therapy and residual disease.

11:20-11:35

- **GS2-03.** Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients.
- **GS5-05.** Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state.

11:35-11:50

- **GS3-02.** PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib.
- KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC).

ATHENS
GREECE
JANUARY 12



An Initiative of
Encore
Medical
Education

11:50-12:05

- **GS5-06.** No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial.
- **GS1-10.** Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE.

12:05-12:20 Discussant

12:20-12:30 Discussion

12:30 – 13:30 Session 5: Adjuvant therapy.

12:30-12:45

- **S2-02.** Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis.
- **GS6-04.** Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter study

12:45-13:00

- **GS2-05.** Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer
- **GS2-04.** Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer

13:00-13:15

- **GS2-07.** PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer.
- The immunomodulatory potential of denosumab in breast cancer: results from DBEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young premenopausal women diagnosed with early breast cancer.

13:15-13:25 Discussion

13:25-14:10. Hellenic Oncology Research Group Award & Lecture.

- Introduction

Eleftherios (Terry) Mamounas

- Neoadjuvant Chemotherapy in Early Breast Cancer: Discovering Tumor Biology, Individualizing Therapy and Improving Outcomes.

14:10-15:00 Lunch break

15:00-15:30. Patient Advocacy session.

- Talking openly about Metastatic Breast Cancer

15:30 – 16:30 Session 6: Insitu disease and hormonal therapy.

15:30-15:45

- **GS3-01.** A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ.
- A phase II pre-surgical trial of lapatinib for the treatment of women with HER2 positive or EGFR positive ductal carcinoma in situ.

15:45-16:00

- **GS3-06.** Dynamics of breast cancer relapse reveal molecularly defined late recurring ER-positive subgroups: Results from the METABRIC study.
- **GS3-03.** Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women.

16:00-16:15

- **GS3-08.** Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial.
- **PD1-11.** nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer.
- SOLT1-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer.

16:15-16:30. Discussion

16:30 – 17:45 Session 7: Immunotherapy and novel therapeutics.

16:30-16:45

- **PD1-06.** A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer (MBC). Lindeman
- **PD1-08.** Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER+) advanced breast cancer (ABC) with progression on endocrine therapy (ET). Jhaveri
- **PD1-09.** Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER positive/HER2-negative metastatic breast cancer previously treated with everolimus. Diamond

16:45-17:00

- **PD8-12.** Safety and efficacy of palbociclib and radiotherapy in metastatic breast cancer patients: Initial results of a novel combination.
- Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results.
- Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA: (TOPACIO/Keynote-162).

17:00-17:15

- An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC).
- Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC).
- **GS1-04.** IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + *nab*-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer.

ATHENS
GREECE
JANUARY 12



An Initiative of
Encore
Medical
Education

17:15-17:30

- Is breast cancer entering in the immunotherapy era?

17:30-17:45 Discussion

17:45-18:00 Coffee break

18:00 – 19:00 Session 8: Supportive and survivorship issues.

18:00-18:20

- **GS5-01.** A randomized community-based trial of an angiotensin converting enzyme inhibitor, lisinopril or a beta blocker, carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving adjuvant trastuzumab.
- **GS5-02.** Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment. Results from the EBBA-II trial.
- **PD8-10.** No increased cardiovascular mortality after twenty years in a randomized trial of radiotherapy after breast conserving surgery, SweBCG 91RT, from the Swedish breast cancer group.

18:20 - 18:35

- **GS5-03.** Lifestyle intervention and effect on disease-free survival in early breast cancer pts: Interim Analysis from the randomized SUCCESS C study
- **GS6-03.** Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results.

ATHENS
GREECE
JANUARY 12



An Initiative of
Encore
Medical
Education

18:35-18:50

- **GS6-02.** A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study 5C-1603.
- **PD6-06.** Impact of BRCA mutations on chemotherapy-induced loss of ovarian reserve: A prospective longitudinal study.

18:50-19:00. Discussion

19:00-19:30. Session 9: What will do on Monday.

19:30-20:00. Closing Remarks